News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
FDA to Meet on Long-Lasting Zyprexa
January 9, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
WASHINGTON -The Food and Drug Administration has scheduled a meeting next month to review the safety and effectiveness of a long-acting version of Eli Lilly & Co.'s schizophrenia drug.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Postmarket research
Regulatory
Eli Lilly and Company
MORE ON THIS TOPIC
Lung cancer
ESMO 2026: Amgen’s Imdelltra slashes death risk by nearly 60% in small cell lung cancer
October 26, 2026
·
4 min read
·
Tristan Manalac
Ovarian cancer
Genmab’s ADC beats survival expectations in Phase 3 ovarian cancer trial
October 26, 2026
·
2 min read
·
Nick Paul Taylor
Insights
Australia’s clinical trial advantage gains ground amid U.S. uncertainty
October 26, 2026
·
4 min read
·
Jennifer C. Smith-Parker
Autoimmune diseases
BMS reveals death from septic pneumonia of multiple sclerosis patient in CAR T trial
October 23, 2026
·
3 min read
·
Heather McKenzie
